Weighing the Impact of Obesity

Obese women with breast cancer are at higher risk for recurrence and death, but new findings suggest it may depend on cancer subtype. 

MELISSA WEBER
PUBLISHED: 1:00 AM, THU DECEMBER 9, 2010
Talk about this article with other patients, caregivers, and advocates in the Breast CURE discussion group.
The research has been pretty clear: Obese women with breast cancer are at higher risk for recurrence and death. But now, new findings suggest the poor outcome for obese patients depends on whether they have the most common subtype—estrogen receptor–positive, HER2-negative breast cancer. 

Obese women treated with chemotherapy after surgery had worse overall survival and disease-free survival than non-obese patients—but only if they had estrogen receptor–positive, or hormone-sensitive, cancers. The findings, presented Thursday at the San Antonio Breast Cancer Symposium, are the first to show that obesity’s harmful effects may be confined to this group of patients. Women with other types of breast cancer, however, shouldn’t consider themselves safe just yet, experts caution.

Obese Americans make up a third of the adult population. A person is considered obese if their body mass index—a calculation of body fat that uses weight in relation to height—is 30 or higher. So a 5-foot-5-inch woman would be considered obese at 180 pounds.

Using information from a previous clinical trial, investigators examined the relationship between body mass index and survival in early-stage patients. When researchers teased out the data by breast cancer subtype, they uncovered a trend toward worse survival only among obese women with hormone-sensitive tumors.

Hoping to confirm this finding, the researchers analyzed data from two other studies—one that included patients with estrogen receptor–positive cancers, and a second that comprised estrogen receptor–positive cancers. HER2 status was unknown in these two studies, but, like the first trial, patients had received chemotherapy after surgical removal of the tumor.

Based on combined data from the three studies, obese patients who do not have hormone-sensitive breast cancer appear to be spared the harmful effects of obesity, said lead investigator Joseph Sparano, MD, professor of medicine and women’s health at Albert Einstein College of Medicine and associate chairman of the department of oncology at Montefiore Medical Center in Bronx, New York. The findings, however, would need to be confirmed in other studies that look at all breast cancer subtypes, Sparano noted. 

Certainly the (women with ER-positive cancers) are at risk, but I wouldn’t begin to reassure the hormone receptor–negative obese women that they are not at risk. At the end of the day, the risk of obesity on prognosis won’t just be present in hormone receptor–positive patients.

Women with estrogen receptor–positive breast cancer should not feel protected, said Pamela Goodwin, MD, a clinician-scientist at Mount Sinai Hospital in Toronto and an associate professor of medicine at the University of Toronto. “Certainly the (women with ER-positive cancers) are at risk, but I wouldn’t begin to reassure the hormone receptor–negative obese women that they are not at risk,” said Goodwin, who was not involved in the study. “At the end of the day, the risk of obesity on prognosis won’t just be present in hormone receptor–positive patients.”

The most likely explanation for the findings may be that high insulin levels—a byproduct of obesity—are driving the growth of breast tumors, said Goodwin.

Talk about this article with other patients, caregivers, and advocates in the Breast CURE discussion group.
Special Feature
Share Your Art
Related Articles
Flat and Fabulous: Life After Breast Cancer and a Double Mastectomy
Learning to accept my body after a double mastectomy.
Freda: Management of Aggressive Treatment and a Difficult Prognosis
Freda Omaswa talks about how she has coped with the emotional and physical aspects of disease progression and the side effects caused by aggressive cancer treatment, and provides suggestions to patients facing a similar situation. Dr John Marshall remarks on the usefulness of maintaining a journal throughout a cancer journey. After a 19-month battle with metastatic colon carcinoma, Freda passed away quietly in her sleep on February 1, 2016.
Improving Care for Patients with Colorectal Cancer
In this segment, Dr John Marshall discusses the importance of patient-patient connections throughout a cancer journey, and the challenges he faces when advising patients, and their loved ones, of the potential for treatment side effects. Freda Omaswa remarks on areas of cancer care where she feels improvements need to be made, and how her experience as a patient will change her as a physician.After a 19-month battle with metastatic colon carcinoma, Freda passed away quietly in her sleep on February 1, 2016.
Related Videos
Amanda L. Kong on Seeking a Second Opinion for Breast Cancer Care at a High Volume Hospital
Amanda L. Kong, discusses why patients should consider seeking a second opinion for their breast cancer diagnosis and care at a high volume hospital.
Amanda L. Kong on Breast Cancer Care at High Volume Hospitals
This study sought to identify patterns of breast cancer care at high volume hospitals.
Anees B. Chagpar on What to Expect After Contralateral Prophylactic Mastectomy
Anees B. Chagpar, director of the Breast Center at Smilow Cancer Hospital at Yale-New Haven, discusses what a patient can expect following a contralateral prophylactic mastectomy.
$auto_registration$